V&V

Vantage MedTech Completes Rebrand with New Website Launch

Retrieved on: 
Wednesday, February 14, 2024
Medical software, FDA, Life, Engineering, Medtech, Connected Devices, Vantage, Software, V&V, Risk management

MOONACHIE, N.J. and LENEXA, Kan., Feb. 14, 2024 /PRNewswire/ -- Vantage MedTech announces the launch of its new website, VantageMedTech.com highlighting its comprehensive life cycle solutions enabling medical device innovations.

Key Points: 
  • MOONACHIE, N.J. and LENEXA, Kan., Feb. 14, 2024 /PRNewswire/ -- Vantage MedTech announces the launch of its new website, VantageMedTech.com highlighting its comprehensive life cycle solutions enabling medical device innovations.
  • The enhanced website experience is the culmination of the previously announced merger of Sterling Medical Devices and RBC Medical Innovations and subsequent rebrand to Vantage MedTech.
  • Discover what makes Vantage MedTech stand out amongst other contract development and manufacturing partners advancing medical technologies:
    Platforms for Accelerated Development- Vantage MedTech's proprietary Advantage Platforms® use established software and hardware architecture as the foundation for a variety of technology solutions.
  • The new Vantage MedTech website demonstrates how our capabilities, innovative expertise and acceleration solutions will ensure our MedTech clients successfully reach their goals."

Kymanox Unveils Product Design, Development, and Commercialization Group Under Leadership of Chief Technology Officer

Retrieved on: 
Thursday, January 4, 2024
Commercialization, V&V, RAC, Entrepreneurship, Verification and validation, New product development, Process engineering, Quality control, EMA, Acquisition, CMC, Doctor of Philosophy, Innovation, Knowledge, Engineering, Quality assurance, Patient, Organization

Newly appointed Chief Technology Officer, Nicholas (Nick) Ciccarelli, PE, who will lead the new group, emphasized the importance of optimal transitions between groups for faster speed to market.

Key Points: 
  • Newly appointed Chief Technology Officer, Nicholas (Nick) Ciccarelli, PE, who will lead the new group, emphasized the importance of optimal transitions between groups for faster speed to market.
  • Ciccarelli stated, "Our approach prioritizes the flow of information and ideas between teams, promoting efficiency at every stage.
  • By doing so, we're confident in our ability to accelerate product development timelines and get innovative solutions to market faster."
  • The newly formed Product Design, Development, and Commercialization group is structured to enhance collaboration and to leverage expertise and knowledge across the entirety of Kymanox’s 300 global employees.

Foretellix and Nuro announce partnership to accelerate safe deployment of autonomous vehicles

Retrieved on: 
Thursday, January 4, 2024
V&V, Partnership, Research, West Hall, Engineering, ODD, LVCC, Safety, CES, System, Automation, Risk management

SUNNYVALE, Calif., Jan. 4, 2024 /PRNewswire/ -- Nuro, a leading autonomous vehicle company, and Foretellix, the leading provider of safety-driven verification and validation (V&V) solutions, today announced a strategic partnership to accelerate the safe and large-scale deployment of autonomous vehicles for last-mile delivery.

Key Points: 
  • SUNNYVALE, Calif., Jan. 4, 2024 /PRNewswire/ -- Nuro , a leading autonomous vehicle company, and Foretellix , the leading provider of safety-driven verification and validation (V&V) solutions, today announced a strategic partnership to accelerate the safe and large-scale deployment of autonomous vehicles for last-mile delivery.
  • This will enable automated virtual testing of the Nuro Driver™ using Foretellix's Foretify™ platform and Nuro's advanced simulator.
  • The Nuro Driver™ is an integrated autonomous driving system consisting of state-of-the-art, AI-first software and custom-built sense and compute hardware.
  • This partnership underscores Nuro's deep commitment to safely commercializing Level-4 autonomous technology at scale across commercial and consumer applications.

Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process

Retrieved on: 
Monday, November 13, 2023
Clinical trial, V&V, ZEUS robotic surgical system, Electromagnetic compatibility, IDE, Verification, EMC, FDA

BRAINTREE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces it had successfully completed the Electromagnetic Compatibility (EMC) testing section of the Verification and Validation (V&V) process.

Key Points: 
  • BRAINTREE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces it had successfully completed the Electromagnetic Compatibility (EMC) testing section of the Verification and Validation (V&V) process.
  • V&V are distinct procedures employed to ensure that a product, service, or system, aligns with specified requirements and effectively serves its intended purpose.
  • The V&V, together with the pre-clinical pivotal study Microbot recently completed, are essential elements to an Investigational Device Exemption (IDE) submission for the FDA to commence clinical trials as part of the pathway for and receiving the required regulatory clearance.
  • “The success in completing the EMC testing of our V&V testing, we believe, affirms our dedication to ensuring the highest quality and safety standards for our LIBERTY Robotic Surgical System.

Foretellix Raises $85 Million in Series C Closing

Retrieved on: 
Tuesday, December 5, 2023
ASAM, V&V, Safety, Entrepreneurship, OurCrowd, Mining, Temasek, Advanced driver-assistance system, Build automation, AV, Quattro (four-wheel-drive system), Growth, Original equipment manufacturer, ADAS, Isuzu

TEL-AVIV, Israel and SUNNYVALE, Calif., Dec. 5, 2023 /PRNewswire/ -- Foretellix, the leading provider of safety-driven verification and validation (V&V) solutions for Automated Driving Systems and Advanced Driver Assistance Systems (ADAS), has announced today that it closed a Series C funding round of $85 million, bringing its total raised capital to $135 million. The funding round was led by 83North. The new investors Temasek and Isuzu joined Woven Capital - the growth fund of Toyota - NVIDIA, and Artofin, which participated in the first closing earlier this year. All major existing shareholders participated, including MoreTech, Nationwide, Volvo Group VC, Jump Capital, Next Gear Ventures, and OurCrowd. Foretellix will use the funding to accelerate the development of its expanding product portfolio and address the growing worldwide demand for its solutions.

Key Points: 
  • The new investors Temasek and Isuzu joined Woven Capital - the growth fund of Toyota - NVIDIA, and Artofin, which participated in the first closing earlier this year.
  • Foretellix will use the funding to accelerate the development of its expanding product portfolio and address the growing worldwide demand for its solutions.
  • "We are thrilled to have Temasek and Isuzu join as investors," said Ziv Binyamini, Foretellix CEO and Co-Founder.
  • Foretellix led the ASAM OpenSCENARIO® 2.0 (OSC2.0) standard development, revolutionizing how safety is developed and tested in Automated Driving Systems.

Foretellix Raises $85 Million in Series C Closing

Retrieved on: 
Tuesday, December 5, 2023
ASAM, V&V, Safety, Entrepreneurship, OurCrowd, Mining, Temasek, Advanced driver-assistance system, Build automation, AV, Quattro (four-wheel-drive system), Growth, Original equipment manufacturer, ADAS, Isuzu

TEL-AVIV, Israel and SUNNYVALE, Calif., Dec. 5, 2023 /PRNewswire/ -- Foretellix, the leading provider of safety-driven verification and validation (V&V) solutions for Automated Driving Systems and Advanced Driver Assistance Systems (ADAS), has announced today that it closed a Series C funding round of $85 million, bringing its total raised capital to $135 million. The funding round was led by 83North. The new investors Temasek and Isuzu joined Woven Capital - the growth fund of Toyota - NVIDIA, and Artofin, which participated in the first closing earlier this year. All major existing shareholders participated, including MoreTech, Nationwide, Volvo Group VC, Jump Capital, Next Gear Ventures, and OurCrowd. Foretellix will use the funding to accelerate the development of its expanding product portfolio and address the growing worldwide demand for its solutions.

Key Points: 
  • The new investors Temasek and Isuzu joined Woven Capital - the growth fund of Toyota - NVIDIA, and Artofin, which participated in the first closing earlier this year.
  • Foretellix will use the funding to accelerate the development of its expanding product portfolio and address the growing worldwide demand for its solutions.
  • "We are thrilled to have Temasek and Isuzu join as investors," said Ziv Binyamini, Foretellix CEO and Co-Founder.
  • Foretellix led the ASAM OpenSCENARIO® 2.0 (OSC2.0) standard development, revolutionizing how safety is developed and tested in Automated Driving Systems.

TIER IV shares verification and validation toolkit for Level 4 autonomous driving functions

Retrieved on: 
Tuesday, November 7, 2023
TIER, Transport in Japan, Data, Safety, Government, AD, Certification, V&V, Level 4, Information, Medical device

TOKYO, Nov. 7, 2023 /PRNewswire/ -- TIER IV , a pioneer in open-source autonomous driving (AD) technology, announces the launch of L4 V&V , a comprehensive evaluation toolkit for verifying and validating Level 4 AD functions.

Key Points: 
  • TOKYO, Nov. 7, 2023 /PRNewswire/ -- TIER IV , a pioneer in open-source autonomous driving (AD) technology, announces the launch of L4 V&V , a comprehensive evaluation toolkit for verifying and validating Level 4 AD functions.
  • With this toolkit, TIER IV will contribute to accelerating the implementation of autonomous driving in society.
  • "By combining TIER IV's L4 V&V and our verification experience, as well as testing technologies utilizing our know-how, we believe we can support our customers with their autonomous driving vehicle development and evaluation for Level 4 autonomous driving approval."
  • Starting with TIER IV's L4 V&V, I look forward to the improvement and advancement of evaluation and verification of autonomous driving in the future."

Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical Study

Retrieved on: 
Tuesday, October 31, 2023
FDA, ZEUS robotic surgical system, Investigational device exemption, V&V, Human, IDE, Clinical trial, Animal, Safety, Investigator's brochure, Nursing

The pivotal study was conducted by three leading interventional radiologists that utilized the LIBERTY Robotic Surgical System to reach a total of 48 animal targets.

Key Points: 
  • The pivotal study was conducted by three leading interventional radiologists that utilized the LIBERTY Robotic Surgical System to reach a total of 48 animal targets.
  • This new data follows the recently announced successful initial outcomes from the pivotal pre-clinical study.
  • A total of 6 LIBERTY Systems were used in the study, each was used to reach a total of 8 targets.
  • "We are excited to share additional positive outcomes of our pivotal pre-clinical study.

Microbot Medical Announces Successful Initial Outcomes from Its Pivotal Pre-Clinical Study with the LIBERTY® Robotic Surgical System

Retrieved on: 
Tuesday, October 17, 2023
ZEUS robotic surgical system, V&V, FDA, Investigational device exemption, IDE, Clinical trial, Human

This pivotal study, together with the verification and validation studies, is expected to serve as the basis for the IDE submission to the FDA

Key Points: 
  • This pivotal study, together with the verification and validation studies, is expected to serve as the basis for the IDE submission to the FDA
    BRAINTREE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces the successful initial outcomes of using the LIBERTY Robotic Surgical System in its pivotal pre-clinical study.
  • The pivotal study was conducted by three leading interventional radiologists that utilized the LIBERTY Robotic Surgical System to reach a total of 48 animal targets.
  • A total of 6 LIBERTY Systems were used in the study, each was used to reach a total of 8 targets.
  • The system operated without any issues in all cases, achieving our initial objectives for the study," said Simon Sharon, CTO & GM.

TTTech Aerospace’s mature TTEthernet® network solutions enable Honeywell Anthem’s™ system architecture

Retrieved on: 
Thursday, September 7, 2023
Software, Networks, Hardware, Technology, Air, Aerospace, Transport, Manufacturing, ARINC, Partnership, ARINC 664, ESA, CSA, Honeywell Aerospace, Orion, AAM, Deterministic Networking, Determinism, TTEthernet, Multimedia, Aircraft, IEEE 802.3, JAXA, IEEE, SAE, Orion (spacecraft), NASA, Anthem, TTP, V&V, Honeywell, Weather, UAM, News, DAL, Airline, Aviation

The highly intuitive and modular/scalable system architecture is enabled by TTTech Aerospace’s open standards-based high-performance TTEthernet network solution (implementing Deterministic Ethernet technology) guaranteeing safe, secure, and reliable data transfers in the avionics network.

Key Points: 
  • The highly intuitive and modular/scalable system architecture is enabled by TTTech Aerospace’s open standards-based high-performance TTEthernet network solution (implementing Deterministic Ethernet technology) guaranteeing safe, secure, and reliable data transfers in the avionics network.
  • It includes very powerful network configuration and qualifiable V&V software tools supporting the setup and integration of TTEthernet networks.
  • TTTech Group has been applying Deterministic Ethernet solutions successfully across a wide range of industries for more than two decades.
  • We are proud to continue our long and successful partnership with Honeywell and to be a part of their future-oriented Honeywell Anthem flight deck solution.”